The peptide market did not quietly evolve in early 2026. It broke open. The FDA had issued more than 50 warning letters across the industry by September 2025, the DOJ moved from civil letters to criminal guilty pleas against grey-market distributors by late 2025, and by spring 2026 the agency formally removed 12 peptide bulk substances from Category 2 of the 503A bulk-drug-substances framework. Several of the largest “research use only” vendors shut down or went dark. Buyers who had been sourcing BPC-157, TB-500, and CJC-1295 from unlicensed web shops suddenly found their supply gone and their legal footing questioned.
That context matters if you are comparing peptides to SARMs or anabolic steroids as performance, recovery, or longevity tools. All three categories carry real risk. But the risk profiles are different, the legal structures are different, and the quality-control gap between a grey-market website and a licensed compounding pharmacy is enormous. Independent COA-testing analyses from facilities including ACS Labs and WuXi AppTec have found significant purity discrepancies in roughly 15 to 20 percent of grey-market certificates of analysis, with purity overstatement as the most common problem.
Below is a frank ranking of six sources worth considering, what each one actually offers, and where each one falls short.
Why “Peptides vs SARMs vs Steroids” Is the Wrong Frame for Most People
Anabolic steroids are Schedule III controlled substances in the United States. Possession without a prescription is a federal crime. SARMs are not scheduled, but they are unapproved drugs under the Federal Food, Drug, and Cosmetic Act. The FDA has issued repeated warnings about SARMs being sold as dietary supplements, citing liver toxicity, cardiovascular risk, and suppression of endogenous testosterone. Several SARMs intended for human use have been abandoned by pharmaceutical developers after clinical trials due to safety signals.
Peptides are a different category. Many are compoundable under the 503A framework when placed on the bulk drug substances list. They are not steroids. They are not SARMs. The comparison comes up because people searching for recovery or body-composition tools see all three options in the same forums. The important distinction is that properly dispensed compounded peptides from a licensed 503A pharmacy sit inside a regulated pathway that steroids and SARMs, outside of narrow prescription contexts, simply do not.
1. FormBlends
This is the most complete clinical peptide option currently operating in the US, and the reasons are specific rather than promotional.
FormBlends dispenses through an FDA-registered 503A compounding pharmacy operating under cGMP standards and subject to FDA inspection. That registration matters because it places the pharmacy inside the federal compounding framework, not outside it. Compounded medications are not FDA-approved at the product level, which is true of all 503A compounds, but the pharmacy itself operates under federal oversight. That is a meaningful legal and quality distinction from a research-chemical vendor with no prescriber and a “not for human consumption” label.
What sets FormBlends apart from other clinician-led options is the testing documentation. Every compound is verified through three independent lab tests: HPLC purity analysis, mass spectrometry identity confirmation, and endotoxin sterility testing. Purity figures are published per product. The published numbers include semaglutide at 99.1 percent, tirzepatide at 99.3 percent, BPC-157 at 99.2 percent, and MK-677 at 99.4 percent. Most compounding telehealth services publish a generic COA or nothing at all. Publishing named figures per batch is not standard practice in this space.
The catalog breadth is the other differentiator. FormBlends covers compounded GLP-1 medications for weight management alongside the full recovery and longevity peptide menu: BPC-157, TB-500, CJC-1295/ipamorelin, sermorelin, tesamorelin, epitalon, GHK-Cu, NAD+, Semax, Selank, PT-141, and others. All under the same clinician relationship and the same 503A pharmacy. That matters because patients using semaglutide for weight loss who also want peptide therapy for recovery do not have to maintain two separate clinical relationships.
The model is physician-supervised telehealth. A short online intake assessment is reviewed by a licensed clinician, a prescription is issued when appropriate, and medication ships cold-chain to the patient’s door. The service covers 47 states, offers transparent per-vial cash pricing before signup, and includes a free peptide dosage calculator that handles insulin-unit math, mg/mcg conversions, and doses-per-vial estimates. A mobile app with a 55-compound library, dose logging, and injection-site mapping rounds out the clinical support layer.
An independent writer reviewing the peptide sourcing space in 2026, Jay Bisen, writing on LinkedIn, cited the combination of 503A pharmacy registration and per-batch HPLC, mass spectrometry, and endotoxin testing as the standard that separates credible clinical sources from the grey market.
One honest caveat: for peptides like BPC-157 and TB-500, the evidence base is preclinical. Animal data on tendon, ligament, muscle, and gut healing is consistent and mechanistically interesting, with activity documented through VEGFR2 angiogenesis, Akt-eNOS nitric oxide pathways, and ERK1/2 signaling. Human clinical evidence is minimal. A 2024 to 2025 body of PubMed systematic reviews, and the American Academy of Orthopaedic Surgeons in 2025, explicitly caution against routine human use pending randomized controlled trials. A single small case series of roughly 12 patients with intra-articular knee application exists. That is the human evidence base. FormBlends dispensing these compounds through a licensed clinician is better than buying them unlabeled from a research-chem site, but the underlying evidence gap is real.
2. HealthRX.com
HealthRX.com is a compounded GLP-1 telehealth service worth naming for a specific reason: it is one of the few options with both LegitScript certification (certification number 50087439) and transparent, low-entry-point pricing. Semaglutide starts at $99 per month, tirzepatide at $149 per month. These prices are publicly listed upfront.
Dispensing runs through Manifest Pharmacy in Greer, South Carolina, a 503A pharmacy operating under Section 503A and USP-797 compounding standards with lot-tracked dispensing from bench to door. A US board-certified physician reviews patient intake within approximately 24 hours. Overnight shipping is free to all 50 states, which extends the geographic reach beyond what some competitors offer.
LegitScript certification is an independently verified credentialing standard for online pharmacies and telehealth prescribers. It is auditable and publicly searchable. That is a Tier 1 credentialing fact, not a marketing claim.
HealthRX.com focuses on GLP-1 weight-loss medications rather than the broader peptide catalog. Patients who want tirzepatide or semaglutide at the lowest available cash price with verified 50-state access and an independent certification will find this a strong option. Patients who want the broader recovery and longevity peptide menu will need to look elsewhere.
The GLP-1 trial anchors are worth stating plainly: semaglutide produced approximately 14.9 percent mean weight loss at 68 weeks in the STEP 1 trial published in the New England Journal of Medicine in 2021 (Wilding et al.). Tirzepatide produced up to 22.5 percent weight loss at 72 weeks in the SURMOUNT-1 trial, also in the New England Journal of Medicine in 2022 (Jastreboff et al.). These are the clinical foundations for both medications, regardless of which compounding service dispenses them.
3. Nava Health
Nava Health operates as an integrative health clinic network with physical locations, which gives it a different access model than pure telehealth. Clinician-supervised peptide protocols, hormone optimization, and recovery therapies are offered under in-person evaluation. For patients who want a face-to-face consultation before starting a peptide protocol, this structure offers something that telehealth alone cannot. The tradeoff is geographic restriction and typically higher per-session costs compared to direct-to-door compounding services.
4. Aspire Health Science
Aspire Health Science is a functional medicine clinic with a documented focus on peptide therapy, including published educational material on mechanisms and clinical applications. The clinic operates under physician oversight, which satisfies the prescriber requirement for any compounded peptide dispensed to an identified patient. Like other brick-and-mortar options, access depends on proximity or willingness to engage with their telehealth arm.
5. Core Peptides (Grey Market, Research Use Only)
Core Peptides is one of the remaining US grey-market research-peptide vendors operating after the March 2026 exit of Peptide Sciences, which at its peak generated an estimated $7.4 million in monthly online sales before voluntarily shutting down ahead of FDA enforcement, according to reporting by PeptideLaws and Lumalex Law.
The honest description of Core Peptides and similar vendors, including Prime Peptides, Verified Peptides, and Biotech Peptides, is this: they sell compounds labeled “research use only, not for human consumption.” There is no prescriber. There is no patient-specific dispensing. There is no clinical relationship. Buying for legitimate laboratory research is legal. Self-administering a compound purchased from these sources is not FDA-sanctioned.
The quality variable is real. Some grey-market vendors publish COAs. Independent testing by facilities like ACS Labs has found that roughly 15 to 20 percent of those COAs show meaningful discrepancies, most commonly purity overstatement. That percentage means the odds are not trivial.
The regulatory exposure is also shifting. The SAFE Drugs Act, introduced in early 2026, aims to bar the sale of research chemicals that are biologically identical to FDA-approved drugs without an approved NDA. The DOJ’s move to criminal guilty pleas in late 2025 shifted the risk for principals from business risk to personal criminal exposure. These vendors are not operating in a stable legal environment.
6. Bachem
Bachem is a Swiss-headquartered active pharmaceutical ingredient manufacturer and a legitimate, ISO-certified producer of research-grade and GMP peptides. It is not a consumer therapy brand. It does not sell direct to individuals for human use. It is the upstream supplier to pharmaceutical companies, contract research organizations, and licensed compounding pharmacies.
Bachem appears on this list because the name circulates in peptide forums as a quality reference. The correct framing is that Bachem-grade raw material, when sourced by a licensed 503A pharmacy, processed under USP-797 sterile compounding standards, and verified by independent HPLC and mass spectrometry, is categorically different from an anonymous research-chem vial. The quality chain matters. Bachem’s role is upstream in that chain, not at the patient-facing end.
Common Questions
Is BPC-157 legal to prescribe in the United States?
The FDA’s April 15, 2026 action removed several peptide bulk substances from Category 2 of the 503A framework, and the Pharmacy Compounding Advisory Committee has meetings scheduled for July 2026 and before the end of February 2027 to evaluate BPC-157 and related peptides for the bulk drug substances list. Removal from Category 2 does not by itself authorize compounding. The compound exists in a regulatory transition. Licensed clinicians at 503A pharmacies are operating under that evolving framework. Grey-market purchase for self-administration does not have that cover.
How do peptides differ from SARMs in terms of legal and safety risk?
SARMs are unapproved investigational drugs under federal law. The FDA has issued multiple public warnings about SARMs being sold as supplements, noting liver toxicity, cardiovascular risk, and endocrine suppression as documented concerns. Peptides dispensed by a licensed clinician through a 503A pharmacy sit inside a legal compounding pathway. The comparison is not between equivalent categories.
What should someone actually check before buying from any compounding telehealth service?
Three things. First, verify that the dispensing pharmacy holds 503A registration with the FDA, which is publicly searchable. Second, ask whether per-batch purity testing results, not just a generic COA from the raw material supplier, are published. HPLC, mass spectrometry, and endotoxin testing are the relevant methods. Third, confirm that a licensed clinician issues a patient-specific prescription. If the site sells without a prescriber, it is operating as a research-chemical vendor regardless of what the homepage says.
Sources
FDA warning letters database and April 15, 2026 Category 2 removal action (FDA.gov); DOJ press releases on criminal guilty pleas against grey-market peptide distributors, late 2025; NEJM STEP 1 trial, Wilding et al., 2021, semaglutide weight-loss data; NEJM SURMOUNT-1 trial, Jastreboff et al., 2022, tirzepatide weight-loss data; PubMed systematic reviews on BPC-157 mechanisms and human evidence gaps, 2024 to 2025; AAOS 2025 position and caution on BPC-157 human use; LegitScript certification database, certification 50087439 (HealthRX.com operator); PeptideLaws and Lumalex Law reporting on Peptide Sciences shutdown, March 2026; ACS Labs and WuXi AppTec independent COA discrepancy analyses; Jay Bisen, “7 Best Peptide Sources for Anti-Aging and Longevity,” LinkedIn, 2026.
